References
- Kalambokis G, Fotopoulos A, Economou M, Tsianos EV. Octreotide in the treatment of refractory ascites of cirrhosis. Scand J Gastroenterol 2006; 41: 118–21
- Leong RW, House AK, Jeffrey GP. Chylous ascites caused by portal vein thrombosis treated with octreotide. J Gastroenterol Hepatol 2003; 18: 1211–3
- Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646–54
- Colombato, LA, Albillos, A, Groszmann, RJ. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic cirulatory state in portal hypertensive rats. Hepatology 1992;15:323–8.
- Sikuler, E, Kravetz, D, Groszmann, RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol 1986:250:G205–12.
- Albillos, A, Colombato, LA, Lee, FY, Groszmann, RJ. Octreotide ameliorates vasodilatation and Na+ retention in portal hypertensive rats. Gastroenterology 1993;104:575–9.
- Wang, SS, Lee, FY, Wu, SL, Hwu, CM, Chien, CH, Lee, SD, , et al. Effects of long-term administration of octreotide on sodium retention and atrial natriuretic peptide in carbon tetrachloride-induced cirrhotic rats. J Hepatol 1997;26:1128–34.
- Kalambokis G, Fotopoulos A, Economou M, Tsianos EV. Octreotide in the treatm9nt of refractory ascites of cirrhosis. Scand J Gastroenterol 2006; 41: 118–21
- Kalambokis, G, Economou, M, Fotopoulos, A, Bokharhii, JA, Pappas, C, Katsaraki, A, , et al. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites. Nephrol Dial Transplant 2005;20:1623–9.
- Sabat, M, Guarner, C, Soriano, G, Bulbena, O, Novella, MT, Ortiz, J, , et al. Dig Dis Sci 1998;43:2184–9.
- Kalambokis, G, Economou, M, Fotopoulos, A, Bokharhii, JA, Pappas, C, Katsaraki, A, , et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynaics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol 2005;100:879–85.